India’s healthcare AI opportunity could become the next big investment story

Every decade, one sector changes how global investors see India. In the 2000s, it was IT services. In the 2010s, consumer internet and fintech rode on Aadhaar, low-cost data and UPI. Healthcare artificial intelligence could be the defining investment story of the next decade. The case rests less on AI hype than on an unusual convergence of public infrastructure, unmet medical need, skilled entrepreneurs and a vast market searching for affordable capacity.

India has already built much of the plumbing. By 12 August 2026, official figures showed 96.43 crore Ayushman Bharat Health Accounts and more than 110 crore linked health records. eSanjeevani has demonstrated telemedicine at population scale, while the National Health Claims Exchange is creating a common digital channel for insurance claims. These are public rails on which private companies can build services, much as fintech firms built businesses on India’s payments infrastructure. The infrastructure is being built at population scale, while the opportunity for private capital lies in turning it into scalable healthcare services that can eventually travel beyond India.

The demand is equally compelling. India’s clinicians and specialists are distributed unevenly, while diabetes, hypertension, cancer and other chronic conditions are rising. Radiologists, pathologists and ophthalmologists remain scarce outside large cities. India cannot train or relocate enough specialists quickly enough to close every gap. Technology that expands a clinician’s reach and productivity therefore solves an economic constraint, not merely a technological problem.


AI can triage chest X-rays in a district hospital, screen retinal images at a primary health centre, flag a deteriorating patient, draft clinical notes and detect incomplete or suspicious claims. Multilingual systems can help patients navigate care in Tamil, Bhojpuri or Odia. The strongest products will keep clinicians accountable for clinical decisions while removing repetitive work and surfacing information at the right moment.

For founders, this opportunity is different from the healthtech cycle of 2021. That cycle often paid to acquire consumers. The next wave will sell measurable value to hospitals, diagnostic chains, insurers, governments and pharmaceutical companies. A hospital may pay for shorter reporting time or fewer readmissions; an insurer for lower leakage; and a clinician network for higher throughput without compromising quality. Sales cycles will be longer than in consumer apps, but contracts built into clinical or financial workflows can be far more durable.

India’s constraints can also become an export advantage. A model designed for modest hardware, intermittent connectivity, several languages and a cost of a few cents per use is relevant across Africa, South-East Asia and Latin America. Founders who prove safety and value in demanding Indian settings can address a much larger Global South market. India should aim to export trusted clinical capability, not simply software licences.

The policy environment is becoming more investable. The Digital Personal Data Protection Act establishes national obligations for personal data. The IndiaAI Mission is expanding access to compute, datasets and indigenous models. Medical-device regulation already gives companies a pathway for software whose intended use makes it a medical device. The remaining need is predictable, risk-based evaluation for AI that learns or changes after deployment.

Healthcare AI can also create deeper moats than a generic software product. Clinical evidence, workflow integration, trusted distribution and regulatory discipline compound over time. A competitor may reproduce an algorithm, but it cannot quickly reproduce years of validated performance, hospital relationships and carefully governed data partnerships.

Three bottlenecks could still waste the opportunity. Startups need representative, de-identified clinical data under transparent governance; otherwise, models trained elsewhere may underperform on Indian patients. Public procurement must move from hardware-style tenders to outcome-based contracts and monitored pilots. Investors must also accept that credible clinical validation and regulatory clearance take time. Healthcare cannot be financed on the assumption that safety is a feature to be added after scale.

The winning teams will combine clinicians, engineers, product builders and policy expertise. They will document performance across regions and patient groups, design for human oversight and prove return on investment. India has built the roads. The next great healthcare companies will build the safest and most useful vehicles for them, and then take those vehicles to the world to address the perennial problems in patient engagement, care delivery and affordable healthcare.

Author is Chairman of Digital Health Associates and one of the key architect of India’s National Health Policy 2017 and NHA.